AtaiBeckley Inc. 4

CFO Michael E. Faerm had 1,275,000 stock options and 285,000 RSUs in AtaiBeckley Inc. automatically cancelled and cashed out for $6.75 per share plus CVRs in connection with the Eli Lilly merger.

On September 11, 2026, in connection with the closing of Eli Lilly and Company's acquisition of AtaiBeckley Inc., all of Chief Financial Officer Michael E. Faerm’s outstanding equity awards were cancelled and cashed out. His stock options covering 1,275,000 shares of common stock were terminated and converted into a right to receive cash equal to the spread between the $6.75 per-share merger price and the option exercise price, plus one contingent value right (CVR) per underlying share, and his 285,000 restricted stock units were similarly cancelled and converted into a cash payment based on $6.75 per share plus one CVR per share. These are transaction-driven, non‑discretionary conversions tied to the merger agreement, and after the effective time Mr. Faerm no longer held company equity as it became a wholly owned subsidiary of Eli Lilly.

Filing Facts

CIK

2081043

Ticker

ATAI

Form

4

Source Type

fda

Accession

0001140361-26-036385

Alert Tier

6